Noteworthy Thursday Option Activity: GM, VKTX, LUNR

Options activity concentrated in Viking Therapeutics (VKTX) and Intuitive Machines (LUNR) showed notable volumes: VKTX saw 29,557 contracts (~3.0 million underlying shares), about 84% of its one‑month average daily volume (3.5M), led by 2,090 contracts in the $50 call expiring Jan 16, 2026 (~209,000 shares). LUNR registered 46,961 contracts (~4.7 million underlying shares), ~78.1% of its one‑month average daily volume (6.0M), driven by 9,783 contracts in the $12 call expiring Dec 19, 2025 (~978,300 shares). These concentrated call trades signal sizable speculative positioning and represent meaningful market technical flows that could influence near‑term price action in the two names.

Analysis

Market structure: The outsized call volumes in VKTX (29,557 contracts ≈3.0M shares, ~84% of ADV) and LUNR (46,961 contracts ≈4.7M shares, ~78% of ADV) signal concentrated demand for long-dated upside (VKTX Jan 16 2026 $50; LUNR Dec 19 2025 $12). Primary beneficiaries are option sellers/market-makers collecting premium and hedging flows; second-order winners are liquidity providers who earn widened spreads. Direct losers are delta-short players and holders of large short interest who may be forced to cover into gamma-driven rallies, increasing short-term squeeze risk of >10-25% moves into expiries.

Risk assessment: Tail risks are classic binary events — VKTX: adverse clinical/FDA outcomes that could wipe 50-90% of call value; LUNR: mission failure, launch delays or capital raises that dilute equity and crush calls. Time horizons split: immediate (0–10 days) — elevated gamma may cause ±10–30% intraday moves; short-term (weeks–months) — IV likely to reprice higher into specific catalysts; long-term (≥12 months) — fundamentals and cash runway dominate. Hidden dependencies include block-sized institutional spreads, hedged collars, or warrants that mimic call flows; margin-triggered liquidations could cascade.

Trade implications: For directional exposure prefer defined-risk option structures to capture skew without unlimited downside — e.g., buy 1x Jan 2026 VKTX $50/$60 call vertical (cap cost, target +100–200% if stock >$60) sized 0.5–2% NAV; for LUNR, use diagonal (Dec25 $12 call + sell nearer-dated call) to monetize term structure. Consider relative trades: long VKTX call vertical vs short 0.5–1% notional position in XBI (beta hedge) to isolate idiosyncratic upside. If IV is >20% above 90-day mean, sell short-dated call spreads against these names to capture mean reversion.

Contrarian angles: Consensus assumes pure bullish retail purchase; alternative explanations — institutional structured products or M&A arbitrage — would behave differently and could unwind quickly. Market-maker delta-hedging can temporarily lift price then reverse when flows stop — a 15–30% reversion is plausible within 2–6 weeks absent fundamental catalysts. Historical parallels: concentrated long-dated call clusters preceded both sustained squeezes (GME 2021) and fast mean-reversions (small-cap biotech pumps); therefore treat current positioning as ephemeral unless company-specific catalysts (trial readouts, launch windows) confirm the move.

Key Decisions for Investors

• Establish a defined-risk long in VKTX: buy Jan 16 2026 $50/$60 call vertical sized 1% NAV (max loss = premium paid). Exit/trim if VKTX > $60 or if IV falls >20% from trade entry, or if negative clinical/press release occurs within 30 days.
• Implement a directional diagonal on LUNR: buy Dec 19 2025 $12 call and sell a near-term (30–60 day) call ~10–20% OTM to finance cost; position size 0.5–1% NAV. Unwind if LUNR rises >25% in 7 trading days or if company announces failed test/launch.
• Sell short-dated call spreads (30–60 day) sized 0.5–1% NAV on either ticker when implied volatility is ≥20% above its 90-day mean to collect premium; close if underlying moves against you >15% intraday or IV spikes further.
• Pair trade to isolate idiosyncratic upside: go long VKTX call vertical (as above) and short XBI equal delta exposure ~0.5% NAV to neutralize sector beta; rebalance weekly and unwind both legs if sector ETF XBI outperforms VKTX by >10% over 30 days.
• Monitor catalysts with hard triggers: for VKTX watch FDA/clinical calendar and cash runway disclosures in next 90 days; for LUNR watch launch windows and gov’t contract announcements — reduce positions by 50% if no confirming catalyst within 60 days.